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ABSTRACT
High-grade conventional osteosarcoma is the most common primary bone 
tumor. Prognosis for osteosarcoma patients is poor and resistance to chemotherapy 
is common. We performed an siRNA screen targeting members of the Bcl-2 family 
in human osteosarcoma cell lines to identify critical regulators of osteosarcoma cell 
survival. Silencing the anti-apoptotic family member Bcl-xL but also the pro-apoptotic 
member Bak using a SMARTpool of siRNAs as well as 4/4 individual siRNAs caused 
loss of viability. Loss of Bak impaired cell cycle progression and triggered autophagy. 
Instead, silencing Bcl-xL induced apoptotic cell death. Bcl-xL was expressed in clinical 
osteosarcoma samples but mRNA or protein levels did not significantly correlate with 
therapy response or survival. Nevertheless, pharmacological inhibition of a range of 
Bcl-2 family members showed that inhibitors targeting Bcl-xL synergistically enhanced 
the response to the chemotherapeutic agent, doxorubicin. Indeed, in osteosarcoma 
cells strongly expressing Bcl-xL, the Bcl-xL-selective BH3 mimetic, WEHI-539 potently 
enhanced apoptosis in the presence of low doses of doxorubicin. Our results identify 
Bcl-xL as a candidate drug target for sensitization to chemotherapy in patients with 
osteosarcoma.
INTRODUCTION
Osteosarcoma is the most common primary 
malignant bone tumor occurring predominantly in the 
second decade of life, and a second peak at middle age. 
It is thought to arise from mesenchymal stem cells that 
can produce osteoid [1–3]. About 30–40% of the patients 
with localized osteosarcoma will relapse mainly by 
presenting with lung metastasis. Approximately 10–20% 
of the patients present with metastasis at the moment 
of diagnosis. Since the introduction of chemotherapy 
patients with local disease have 50–60% long-term 
survival rate. There has been no significant further 
improvement over the past three decades [4]. Following 
disease relapse, prognosis is very poor with 23–33% 
5-year overall survival despite repeated metastasectomies 
when feasible [5].
Apoptosis is a form of programmed cell death, 
which requires caspase-mediated proteolysis, and 
is governed by the Bcl-2 family. It is essential for 
development and tissue homeostasis, and can mediate 
cell death upon exposure to pathogens, cytotoxic agents, 
or oncogenic stress [6]. The Bcl-2 family includes BH3-
only proteins (Bim, Puma, Bad, Noxa, Bik, Hrk, Bmf and 
tBid), pro-survival proteins (Bcl-2, Bcl-xL, Bcl-w, Mcl-1, 
Bfl-1, and Bcl-B) and pro-apoptosis proteins (Bax, Bak 
and Bok). Bok is primarily localized to ER and Golgi 
membranes where it was found to be important for a 
proper ER stress response. Its overexpression induces 
apoptosis in a manner that is dependent on Bax and Bak 
[7]. Bak is localized to mitochondria and Bax resides 
in the cytosol. Once Bak and Bax are activated, they 
undergo conformational changes and Bax localizes to the 
mitochondria. In the mitochondria, Bak and Bax form 
Oncotarget36114www.impactjournals.com/oncotarget
hetero and oligomers which lead to mitochondrial outer 
membrane permeabilization and cytochrome-c release, 
which is necessary for caspase activation [8]. Under 
normal conditions, the pro-survival Bcl-2 members form 
heterodimers with Bax or Bak inhibiting their activation. 
However, under cytotoxic stress the activated BH3-only 
proteins displace these proteins allowing Bax and Bak 
to cause cytochrome-c release from the mitochondria, 
caspase cascade activation, and ultimately cell death [8, 9].
Impaired apoptosis is one of the hallmarks of cancer 
[10]. It allows cancer cells to tolerate oncogenic stress and 
survive in hostile environments such as hypoxic conditions. 
Furthermore, defects in apoptosis in cancer cells can 
hamper the response to chemotherapy [11]. In this study 
we used RNA interference and pharmacological inhibition 
to identify members of the Bcl-2 family that control 
osteosarcoma cell survival and resistance to chemotherapy.
RESULTS
Identification of Bcl-xL as a critical pro-survival 
factor in osteosarcoma cells
An siRNA screen was performed in U2OS cells to 
identify Bcl-2 family members required for osteosarcoma 
cell viability (See Supplementary Figure S1 for screen 
layout and results). The screen was performed in duplicate 
with two negative controls, siGapdh and MOCK (only 
transfection reagent), and siKif11 as positive control (all 
controls were present in triplicate in each plate). Each 
value was normalized to siGapdh, which was set as 
100% viability. MOCK transfected cells showed the same 
viability as siGapdh. To select hits causing loss of viability 
we calculated the standard deviation across each plate, 
and determined that a gene was a hit if the SMARTpool 
(comprised of 4 single siRNAs targeting the same gene) 
and the 4 single siRNAs tested individually, each were 
two standard deviations separated from siGapdh. Using 
this criteria 7 genes were selected, which included Bcl-B, 
Bak, Bid, Bfl-1, Mcl-1, Bok and Bcl-xL (Figure 1A 
and 1B). To assess whether loss of viability was due to 
apoptosis, a caspase 3/7 assay was performed. Caspase 
3 and 7 are effector caspases that once activated, lead to 
cell death by cleaving important structural proteins, and 
causing DNA fragmentation and membrane blebbing [12]. 
Bcl-xL knockdown caused the highest caspase3/7 activity 
after 48 hours of transfection indicating that it effectively 
triggered apoptosis (Figure 1C).
Silencing Bak leads to autophagy in 
osteosarcoma cells
Surprisingly, the screen also identified pro-
apoptotic Bcl-2 family members, including Bak, Bid 
and Bok (Figure 1A–1B). A caspase activity assay 
indicated that the loss of cell viability caused by 
siRNAs targeting these genes was not due to apoptosis 
(Figure 1C). It has been described that failure to 
activate apoptosis in Bak/Bax double knockout cells 
is accompanied by increased autophagy [13, 14]. 
Autophagy is a recycling process that provides building 
blocks and energy during cell stress while unlimited 
autophagy leads to cell death [15]. We first assessed 
the knockdown efficiency of Bak in U2OS cells and 
confirmed a ~100% efficacy (Figure 2A). Since there 
was no caspase 3/7 activation in response to Bak 
knockdown, we next determined if the observed loss of 
cells was due to slower proliferation. Phospho(ser10)-
HistoneH3, a marker for cells in mitosis and Ki67, a 
marker for proliferating cells were analyzed in cell 
lysates and by immunocytochemistry, respectively. 
Silencing Bak in U2OS or MOS cells caused a reduction 
in phospho(ser10)-HistoneH3 levels (Figure 2B) and 
attenuated proliferation was confirmed by reduced Ki67 
staining in si-Bak treated cells (Figure 2C).
To assess if Bak depletion triggered autophagy 
as shown in other systems [11, 12], we determined the 
conjugation of the LC3 protein to phosphatidylethanolamine. 
This conjugation represents a critical step in the formation 
of the autophagosome, a double-membrane organelle 
that engulfs cellular components during autophagy and 
subsequently fuses with the lysosome [16]. Silencing 
Bak in U2OS and in MOS cells led to accumulation of 
the conjugated form of LC3, termed LC3-II (Figure 2D). 
Moreover, treatment of U2OS cells in which Bak was 
silenced with 10 μM chloroquine for 4 hours (chloroquine 
acidifies the phagosome inhibiting its fusion with the 
lysosome leading to autophagosome accumulation [17]) led 
to further accumulation of LC3 II (Figure 2E). In addition, 
immunocytochemistry showed that mitochondria no 
longer distributed throughout the cytoplasm but clustered 
perinuclearly in Bak-depleted cells where they colocalized 
with LC3-marked autophagosomes (Figure 2F). Together, 
these findings indicate that depletion of Bak in osteosarcoma 
cells induces altered mitochondrial distribution, decreased 
proliferation, and autophagy.
Bcl-xL is expressed in osteosarcoma lung 
metastasis
As Bcl-xL silencing caused severe loss of viability 
and led to the strongest induction of caspase 3/7 activity, 
we decided to further study its role in osteosarcoma. 
Others have reported that high Bcl-xL mRNA expression 
in osteosarcoma patients is correlated with lower 
overall survival rate [18]. We analyzed Bcl-xL mRNA 
expression using a previously published microarray data 
set of a cohort of 88 osteosarcoma patients but did not 
observe significant association with overall survival 
(Figure 3A). We next analyzed the expression of Bcl-
xL by immunohistochemistry in 60 human primary 
osteosarcomas and 23 osteosarcoma lung metastases. 
Expression of Bcl-xL was detected in the majority of 
osteosarcoma samples and expression was higher in 
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Figure 1: Identification of Bcl-xL as a candidate target for sensitization to doxorubicin. A. Average U2OS viability in wells 
transfected with siRNA SMARTpools targeting the indicated genes relative to siGapdh. Mean and standard deviation is shown. Horizontal 
line marks 2 SD threshold (<48.4% viability), hits are indicated in black, positive and negative controls in grey. B. Validated hits where all 4 
single siRNAs mimic the SMARTpool and are below the threshold. Black bars represent the SMARTpool and grey patterned bars represent the 
single siRNAs. C. Caspase3/7 activity in U2OS cells transfected with SMARTpool siRNAs targeting the indicated genes. Values were normalized 
to control siGapdh. One representative experiment of two performed in quadruplicate is shown. Error bars represent standard deviation.
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metastases compared to primary tumors (Figure 3B, 3C). 
However, contrary to our expectations, high Bcl-xL protein 
expression levels (SUM score of intensity and % positive 
cells) in primary biopsies correlated with good response to 
therapy in this study (>90% necrosis post-chemotherapy) 
(Figure 3D). Furthermore, event-free survival rates did 
not significantly differ between patients with high and 
low Bcl-xL expression in diagnostic biopsies (Figure 3E). 
These results indicate that Bcl-xL is expressed in advanced 
osteosarcomas, but its expression is not correlated with 
poor therapy response or survival.
Pharmacological inhibition of Bcl-xL sensitizes 
osteosarcoma cells to chemotherapy
Although we could not confirm earlier observations 
correlating Bcl-xL expression to patient survival, our 
siRNA screen indicated that Bcl-xL inhibition might 
Figure 2: Silencing Bak triggers autophagy in osteosarcoma cells. A. Western blot analysis of Bak knockdown efficiency in 
U2OS cells. B. Western blot analysis of phospho(ser10)-HistoneH3, total HistoneH3, and tubulin loading control in U2OS and MOS cells 
transfected with control or Bak siRNA. C. Ki67 staining in control (siGapdh) and siBak transfected U2OS cells 48 hours post-transfection 
(Ki67 antibody, green; Hoechst 33342, blue. D. Western blot analysis of LC3 showing LC3-I (upper band) and –II forms in MOS and U2OS 
cells transiently transfected with siGapdh or siBak SMARTpools. E. Western blot analysis of LC3 in control U2OS cells (MOCK) or U2OS 
transiently transfected with siBak SMARTpool and treated with or without 10 μM chloroquine for 4 hours. F. Control MOS cells (MOCK) 
or MOS cells transiently transfected with siBak for 48 hours, exposed to MitoTracker® (red) for 45 min, fixed and stained with anti-LC3 
(green), and Hoechst 33342 (blue). i, MitoTracker only; ii, merge of all three channels.
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Figure 3: Bcl-xL expression in osteosarcoma clinical samples. A. Kaplan–Meier curve showing relation between Bcl-xL mRNA 
expression level and overall survival in a panel of 88 osteosarcoma patients. The cohort was divided into high and low expression at the 
median. The curve was made using http://r2.amc.nl. p value was determined by Bonferroni testing. B. Sum score (% plus intensity of 
staining) of Bcl-xL expression in all tumors included in the tissue microarray; average is shown in red. Biopsies and metastases from the 
same patient are indicated in green (n = 12); p-value determined by paired t-test. Unpaired biopsies (n = 59) and metastases (n = 7) are 
indicated in black; p-value determined by unpaired t-test. C. Representative images of Bcl-xL expression in primary osteosarcoma biopsy 
and metastasis. Images made with 40x Lens. D. Bcl-xL expression in biopsies of poor and good responders to chemotherapy. P-value 
determined by unpaired two-tailed t-test. E. Event free survival related to Bcl-xL expression in tissue microarray. Tumors were divided 
according to low (mean sum score ≤3; blue line (n = 40)) or high Bcl-xL expression (mean sum score >3; green line (n = 29)). p-value 
determined by Log-rank test.
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enhance tumor killing in cases where it is expressed. 
Therefore, we assessed whether Bcl-xL represents a 
relevant target for osteosarcoma alone or in the context 
of conventional chemotherapy. First, four human 
osteosarcoma cell lines were treated with ABT-737, a BH3 
mimetic that inhibits Bcl-w, Bcl-xL and Bcl-2; of which 
only Bcl-xL was identified in the siRNA screen (Figure 
1A). In addition, HA14-1, a selective Bcl-2 inhibitor was 
tested. All the cell lines showed loss of cell viability in the 
10 μM range for ABT-737 and at higher concentrations for 
HA14-1 (Figure 4A and 4B). Subsequently, we asked if 
these inhibitors, when used at lower concentrations, could 
sensitize osteosarcoma cells to chemotherapy. The four 
osteosarcoma cell lines were co-treated with a suboptimal 
concentration of ABT-737 and a dose range of doxorubicin 
for 72 hours. At a concentration of 2.5 μM of ABT-737, 
viability of the cells was close to 100%. MOS, U2OS 
and to a lesser extent KPD and ZK58 showed increased 
sensitivity to treatment with 50–500 nM doxorubicin 
under these conditions (Figure 4C). By contrast, treatment 
with up to 10 μM of the Bcl-2 selective inhibitor, HA14-1 
did not affect sensitivity to doxorubicin. Indeed, 
calculation of the deviation from additivity as predicted by 
Bliss independence model [19] indicated synergy between 
ABT-737 and doxorubicin (Figure 4D).
We next determined if synergy was due to 
enhanced apoptosis in the presence of the combination 
of ABT-737 and doxorubicin. For this purpose, real time 
imaging was used to detect labeled Annexin V binding 
to phosphatidylserine, a phospholipid that translocates 
Figure 4: Pharmacological inhibition of Bcl-xL sensitizes osteosarcoma cells to chemotherapy. A, B. Dose response 
curve for ABT-737 (A) and HA14-1 (B) in the indicated human osteosarcoma cell lines. Error bars represent the standard deviation of 
two experiments performed in triplicate. Cells were exposed for 72 hours. C. Dose response curves for doxorubicin in the indicated 
osteosarcoma cell lines in absence (black circle) or presence of 2.5 μM ABT-737 (red square) or 10 μM HA14-1 (blue triangle). Cells were 
exposed for 72 hours. Error bars represent mean ± SEM of three experiments. D. Bar graph presenting the percentage of deviation from 
Bliss additivity based on data shown in C. One representative of three independent experiments is shown.
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to the outer lipid layer of the membrane when cells enter 
apoptosis [20]. In agreement with the viability assays 
(Figure 4C), ZK58 cells showed significant Annexin V 
labeling already in response to 2.5 μM ABT-737 alone 
(Figure 5). However, in U2OS and KPD cells exposed to 
2.5 μM ABT-737 or 0.1 μM doxorubicin alone, Annexin 
V labeling was absent or appeared at late time points after 
exposure whereas the combination of 2.5 μM ABT-737 
and 0.1 μM doxorubicin caused rapid, strong Annexin 
V labeling. Moreover, this enhanced response to the 
combination of ABT-737 and chemotherapy was abolished 
in the presence of the pan-caspase inhibitor z-VAD-fmk 
(Figure 5). These results indicate that ABT-737, but not 
the Bcl-2 selective inhibitor HA 14–1 can sensitize human 
osteosarcoma cells to chemotherapy leading to enhanced 
apoptosis.
Inhibition of Bcl-xL with WEHI-539 sensitizes 
osteosarcoma to doxorubicin
To further pinpoint the sensitization to chemotherapy 
to inhibition of Bcl-xL, we made use of a recently 
developed Bcl-xL-selective BH3 mimetic, WEHI-539 
[21]. Exposing U2OS and MOS cells to this compound 
caused loss of viability at concentrations between 1–10 
μM and a similar response was seen in KPD and ZK58 
cells at concentrations >10 μM (Figure 6A). Moreover, a 
suboptimal dose of 1 μM WEHI-539 effectively enhanced 
the response to low doses of doxorubicin in U2OS and 
MOS cells but showed no effect in KPD, ZK58, MNNG, 
MG-63 and Saos-2. (Figure 6B). This difference could 
be attributed to differences in Bcl-xL expression: Bcl-xL 
protein levels were high in U2OS and MOS as compared 
to the other cell lines (Figure 6C). Lastly, we investigated 
whether sensitization to doxorubicin in the presence of 
WEHI-539 was due to enhanced apoptosis. Indeed, MOS 
and U2OS cells exposed to 1 μM WEHI-539 showed 
2–3-fold higher induction of caspase 3/7 activity in 
response to 0.1 μM doxorubicin, which by itself had little 
or no effect (Figure 6D). In agreement with the absence of 
synergy observed in KPD and ZK58 (Figure 6B), WEHI-
539 failed to increase caspase activation in response to 
doxorubicin in these cells (Figure 6D). Altogether, these 
findings demonstrate that osteosarcoma cells expressing 
Bcl-xL can be sensitized to chemotherapy through 
pharmacological Bcl-xL inhibition.
DISCUSSION
Patients with metastatic or recurrent osteosarcoma 
present low probability of survival mainly due to 
resistance to standard chemotherapy [22, 23]. Bcl-2 family 
proteins play a crucial role in regulating cell survival/cell 
death pathways, and aberrations in their expression or 
function mediates tumor development and progression 
[24]. Our siRNA screen identifies anti-apoptosis genes 
such as Bcl-xL, Mcl-1 and Bfl-1, but interestingly, it 
also identified pro-apoptosis genes such as Bak, Bok and 
Bid. Autophagy was reported to be enhanced in Bak/Bax 
double knockout cells in response to death stimuli such 
as radiation and cytotoxic drugs [25, 26]. Others have 
associated cell cycle arrest with Bak/Bax double knockout 
conditions [27, 28]. We identify both aspects in Bak-
silenced osteosarcoma cells: the cells proliferate slower 
and autophagy is activated. We also notice a recruitment of 
mitochondria to the perinuclear area where they colocalize 
Figure 5: Inhibition of Bcl-xL in combination with doxorubicin leads to enhanced apoptosis. Live imaging of Annexin V 
accumulation in MOS, U2OS and ZK58 cells. Cells were treated with DMSO, 0.1 μM Doxorubicin, 2.5 μM ABT-737, or the combination 
with or without zvad-fmk as indicated. Graphs represent one of three independent experiments. Annexin V was quantified with ImagePro 
Analyzer 7.0.
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with autophagosomes, which may point to mitoautophagy. 
Alternatively, this may reflect the recent demonstration 
that mitochondria can in fact contribute to the formation 
of the autophagosome membrane [29].
Bcl-xL expression has been associated with poor 
prognosis for patients with colorectal cancer [30] and 
hepatocellular carcinoma [31]. In colorectal cancer, 
high expression of Bcl-xL correlates with lymph node 
metastasis and poorer survival [32]. In melanoma the 
expression of Bcl-xL is correlated with tumor thickness 
and disease free survival [33], and in follicular lymphoma 
it is correlated with overall survival [34]. Bcl-xL 
expression has also been associated with resistance to 
cytotoxic agents in ovarian cancer [35]. Furthermore, 
the correlation between Bcl-xL expression and 
chemoresistance has been demonstrated in the NCI panel 
of 60 cell lines to be independent of p53 status [36].
In osteosarcoma, patients with high Bcl-xL mRNA 
levels have been reported to have a lower probability of 
5-year overall survival [18]. We were not able to reproduce 
such a correlation in our dataset. Moreover, although in 
our study Bcl-xL protein was expressed in osteosarcoma 
Figure 6: Inhibition of Bcl-xL with WEHI-539 sensitizes osteosarcoma to doxorubicin. A. WEHI-539 dose response curves 
for the indicated human osteosarcoma cell lines. Cells were exposed for 72 hours. Error bars represent standard deviation of two experiments 
performed in triplicate. B. Doxorubicin dose response curves for the indicated osteosarcoma cell lines in absence (black circles) or presence 
of 1 μM WEHI-539 (red squares). Cells were exposed for 72 hours. Mean ± SEM of three experiments is shown. C. Western blot analysis 
of Bcl-xL expression in the indicated osteosarcoma cell lines. D. Caspase 3/7 activity in the indicated osteosarcoma cell lines exposed to 
DMSO, 0.1 μM doxorubicin, 1 μM WEHI539 or the combination (mix). Mean ± SEM of three experiments is shown.
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biopsies and levels were higher in metastases, no 
correlation with poor response to chemotherapy was 
observed. The reason for this difference between our own 
observation and that of others [18] is currently unknown. 
Nevertheless, in line with the common role of anti-
apoptotic Bcl-2 family members in cancer resistance to 
cytotoxic therapy [37, 38] we find that Bcl-xL inhibition 
can sensitize osteosarcoma cells to low dose chemotherapy.
ABT-737, a small molecule inhibitor of Bcl-xL, Bcl-
2 and Bcl-w, was discovered in 2005 and found to enhance 
the cytotoxic effect of chemotherapy and radiation [39]. 
Studies in myeloma cells [40], myeloid leukemias [41], 
neck-squamous cell carcinoma [42], gastrointestinal 
stromal tumor cells [43], and chondrosarcoma [38] 
indicated that ABT-737 treatment sensitizes to 
chemotherapy and other cytotoxic agents [44]. We show 
that a similar strategy may be relevant in the context of 
human osteosarcoma. However, a major limitation for 
translation to the clinic is the fact that ABT-737 is not 
orally bioavailable, which limits flexibility of dosing 
regimens. ABT-263 is an analogue of ABT-737 with oral 
bioavailability, which also potently inhibits Bcl-xL, Bcl-2 
and Bcl-w [45]. It has been demonstrated to have little 
activity as a single agent in a phase II clinical trial [46] but 
to enhance the effect of other cytotoxic agents [47–49]. 
The Bcl-xL-selective BH3 mimetic, WEHI-539 used in 
our current study has shown in vivo toxicity that hinders 
further clinical studies. Recently, a related Bcl-xL-selective 
inhibitor, A-1155463, has been synthesized lacking the 
toxic moiety [50]. Based on our current study, it will be of 
particular interest to assess how such a pharmacological 
inhibitor affects the sensitivity of chemoresistant 
osteosarcomas. High Bcl-xL protein expression as detected 
by IHC may serve as a biomarker for treatment with Bcl-
xL inhibitors alone or in the presence of chemotherapy. 
Such a strategy, would potentially allow reduced dosage 
of doxorubicin, thereby decreasing toxicity. Follow up 
preclinical studies, for instance using xenograft models, 
will have to determine efficacy and toxicity associated with 
different concentrations of Bcl-xL inhibitors, doxorubicin, 
and combinations. Our findings suggest that such studies 
are warranted to open the possibility for further clinical 
studies in patients with osteosarcoma.
MATERIALS AND METHODS
Reagents and antibodies
Doxorubicin was obtained from the Pharmacy 
at the Leiden University Academic Hospital, ABT-
737, UMI-77 and HA14-1 were from SelleckChem 
(Huissen, Netherlands). WEHI-539 was from ApexBio 
(Texas, U.S.A.). The pan-caspase inhibitor z-VAD-
fmk was obtained from Bachem (Weil am Rhein, 
Germany). The Bcl-xL antibody (clone 54H6) used for 
immunohistochemistry, the Bcl-xL antibody (2762s) 
used for Western blot and Bak antibody were from Cell 
Signaling (Bioké, Leiden, The Netherlands). LC3 antibody 
was from Novus Biologics (Cambridge, England) and 
Ki67 was from Abcam (Cambridge, England). Chloroquine 
was bought from Sigma Aldrich (Zwijndrecht, The 
Netherlands). Hoechst 33342 was purchased from Fischer 
Scientific (Bleiswijk, The Netherlands).
Immunohistochemistry on tissue microarrays
Two tissue microarrays used in this study were 
previously constructed with one was previously published 
[3]. The second tissue microarray consisted of 73 FFPE 
biopsies, resections and metastases mainly from high 
grade conventional osteosarcomas. All specimens in this 
study were handled according to the ethical guidelines 
described in ‘Code for Proper Secondary Use of Human 
Tissue in The Netherlands’ of the Dutch Federation of 
Medical Scientific Societies. The slide was deparaffinized, 
rehydrated and blocked of endogenouse peroxidase. 
Subsequently, antigen retrieval was performed with citrate 
pH 6.0. Incubation with antibody was overnight at 4°C at 
a 1:1000 dilution. As a second step we used Immunologic 
Poly-HRP-GAM/R/R IgG (DVPO110HRP) and Dako 
liquid DAB+ Substrate Chromogen System (K3468), 
followed by counterstaining with hematoxylin. Testis tissue 
was used as control. Slides were scored independently 
by two observers (JVMGB and YJ). Staining intensity 
(0 = absent, 1 = weak, 2 = moderate, 3 = strong) and 
extent of the staining (0 = 0%, 1 = 1–24%, 2 = 25–49%, 
3 = 50–74% and 4 = 75–100%) were assessed. The two 
values were added to obtain sum scores. Cores where the 
tissue was lost were excluded from the analysis. To assess 
response to chemotherapy, patients were divided among 
good and poor responders. The histological response was 
assessed by determining the amount of necrotic tissue 
in the resection specimen obtained after chemotherapy. 
Response was considered good when a patient presented 
more than 90% necrotic tissue in the tumor, and bad 
responders were those with less than 90% necrosis [51].
Cell culture
Human osteosarcoma cell lines MOS, U2OS, 
143B, ZK58, KPD, MNNG, MG-63 and Saos-2 were 
previously described [52, 53]. Cells were grown in 
RPMI1640 medium supplemented with 10% fetal bovine 
serum and 25 U/mL penicillin and 25 μg/mL of penicillin-
streptomycin. All cells were cultured in a humidified 
incubator at 37°C with 5% CO2.
siRNA screen
Transient knockdown of individual genes in U2OS 
cells was achieved using siRNAs from Dharmacon, GE 
(Landsmeer, Netherlands). The end concentration of siRNA 
was 20 nM and it was delivered to the cells with INTERFERin 
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siRNA transfection reagent by reverse transfection according 
to the manufacturer’s procedures (Polyplus transfection, 
Leusden, Netherlands). The transfection was performed in 
u-clear 96-well plates from Corning. Nineteen Bcl-2 family 
members were targeted with a SMARTpool comprised of 4 
different siRNAs and with each single siRNA individually. 
After 24 hours of transfection the medium was refreshed and 
the cells were further incubated for 72 hours. Alamar Blue 
was acquired from Thermo Fisher Scientific (Bleiswijk, The 
Netherlands) and used to assess viability as specified by the 
manufacturer. Fluorescence was measured with a FluoStar 
Optima plate reader.
Microarray data analysis
Gene expression profiles were obtained from a 
previously published microarray data set [54]. Using the 
Bioconductor lumi package, data was transformed with 
the variance stabilizing transformation algorithm and 
normalized with the robust spline normalization algorithm. 
Probe_ID identifiers from the Illumina Annotation 
for Illumina human-6 v2.0 expression beadchip were 
used as reporters (Bcl-xL reporter = ILMN_1654118). 
Kaplan Meier curves were created from the entry “Mixed 
Osteosarcoma-Kuijer-127-vst-ilmnhwg6v2” in the web 
application R2 (http://r2.amc.nl).
Immunoblotting
Cells were lysed with SDS protein buffer (125 
mM Tris/HCl pH 6.8, 20% glycerol, 4% SDS and 0.2% 
bromophenol blue). Proteins were resolved by SDS-PAGE 
and transferred to polyvinylidine difluoride membrane. 
Membranes were blocked in 5% BSA-TBST (TRIS-
0.05% Tween20), followed by overnight incubation with 
primary antibodies and 45 minutes incubation with HRP-
conjugated secondary antibodies. Chemoluminescence 
was detected with the bioimager LAS400 (GE Healthcare).
Immunostaining
MOS and U2OS cells were transfected with siRNA 
as previously described. The cells were fixed 48 hours 
after transfection with ice cold methanol for 15 minutes, 
and were subsequently rinsed 3 times for 5 minutes with 
PBS. Afterwards, the cells were incubated with blocking 
solution [10% normal goat serum, 0.3%Triton100 in PBS] 
for 1 hour, rinsed 3 times for 5 minutes with PBS, and 
then incubated 1 hour with second antibody(1:300). Nuclei 
stainig with Hoechst 33342 was performed as a final step 
together with the rinsing steps. The antibodies were diluted 
in antibody staining solution [1%BSA, 0.3%Triton100 in 
PBS]. The cells probed mitochondria, were exposed to 75 
nM of MitoTracker® Red CMX Ros (from Cell Signaling) 
for 45 minutes previous to fixation. All images were taken 
with confocal microscope Eclipse Ti-E from Nikon.
Cell viability, and real time apoptosis assays
For cell viability assays (excluding the siRNA 
screen), cells were processed using the ATPlite 1Step 
kit (Perkin Elmer) according to the manufacturer’s 
instructions, followed by luminescence measurement in a 
Fluostar Optima plate reader. Apoptosis was assessed by 
Annexin V staining and Caspase Glo3/7 (Promega). For 
real time Annexin V binding assays, cells were co-exposed 
to drugs and Annexin V in a u-clear 96-well plate, and 
imaged every hour, for 66 hours. Images were obtained 
using a BD Pathway 855, then converted to videos, and 
Annexin V staining was quantified by an in-house macro 
for Image-Pro Analyzer 7.0 as previously described [20]. 
For caspase 3/7 activity measurements, cells were exposed 
to the drug for 24 hours after which the reagent was added 
1:1. Luminescence was measured in a Fluostar Optima 
plate reader.
Synergy assessment
To assess synergy, we used the Bliss independence 
model, which defines to what extent the effect of a drug 
at a certain concentration is independent of the presence 
of the other drug at a certain concentration [55]. This 
model predicts the combined response C for two single 
compounds with effects A and B: C = A+B – A*B [56].
Statistical analysis
Dose response curve fitting and all statistical 
analyses were performed with GraphPad Prism 5.0 
(GraphPad Software, La Jolla, CA). The unpaired and 
paired two-tailed t-test used to compare groups in Figure 
3B and 3D was performed with IBM SPSS statistics 
20. Event free survival was computed from the date of 
diagnosis until first recurrence, either local or metastatic. 
Tumors were divided into two groups, having low (mean 
sum score ≤ 3) or high Bcl-xL expression (mean sum score 
> 3). Event free survival in both groups was compared 
using the Kaplan-Meier method and the Log-rank test with 
IBM SPSS statistics 20.
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